NIH Public Access

Author Manuscript
FEBS Lett. Author manuscript; available in PMC 2015 January 21.
Published in final edited form as:
NIH-PA Author Manuscript

FEBS Lett. 2014 January 21; 588(2): 253–260. doi:10.1016/j.febslet.2013.11.035.

Recent advances in mammalian protein production

Ashok D. Bandaranayake1 and Steven C. Almo1,2
1Department of Biochemistry, Albert Einstein College of Medicine, 1300 Morris Park Avenue,

Bronx, NY 10461
2Department of Physiology and Biophysics, Albert Einstein College of Medicine, 1300 Morris Park
Avenue, Bronx, NY 10461

Abstract
Mammalian protein production platforms have had a profound impact in many areas of basic and
applied research, and an increasing number of blockbuster drugs are recombinant mammalian
proteins. With global sales of these drugs exceeding US$120 billion per year, both industry and
academic research groups continue to develop cost effective methods for producing mammalian
NIH-PA Author Manuscript

proteins to support preclinical and clinical evaluations of potential therapeutics. While a wide
range of platforms have been successfully exploited for laboratory use, the bulk of recent biologics
have been produced in mammalian cell lines due to the requirement for post translational
modification and the biosynthetic complexity of the target proteins. In this review we highlight the
range of mammalian expression platforms available for recombinant protein production, as well as
advances in technologies for the rapid and efficient selection of highly productive clones.

Keywords
protein production; mammalian expression; therapeutics; clonal selection

Introduction
The ability to produce mammalian proteins in recombinant systems has had a profound
impact in many areas of basic and applied research, as well as the biotech sector. While
academic research groups require recombinant mammalian proteins for functional analysis
(e.g. cellular signaling pathways) and high resolution structure determination, the biotech
NIH-PA Author Manuscript

sector has heavily invested in the production of protein therapeutics (i.e. biologics), as a
relatively new and transformative approach to treating human diseases. An increasing
number of blockbuster drugs are recombinant mammalian proteins and the United States
Food and Drug Administration (FDA) has approved over 100 recombinant protein
therapeutics to date [1]. With this success, both industry and academic research groups
continue to develop cost effective methods for producing mammalian proteins to support
pre-clinical and clinical evaluations of potential therapeutics.

The need for multi-milligram quantities of recombinant mammalian protein in the academic
sector is, in part, driven by focused and team-based structural biology initiatives, such as the
New York Structural Genomics Research Consortium (NYSGRC) [2] [http://
www.nysgrc.org/psi3-cgi/index.cgi], as well as pre-clinical research. The screening of 10–

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our
customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of
the resulting proof before it is published in its final citable form. Please note that during the production process errors may be
discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
 Bandaranayake and Almo Page 2

20 constructs may be required to obtain the multi-milligrams yields needed for successful
structure determination [3]. As our understanding of cellular signaling pathways grow, so
does the need for structural characterization of the signaling components and more
NIH-PA Author Manuscript

importantly, structures of the relevant multi-component protein assemblies. As the tools for
producing these mammalian proteins improve so does the complexity and value of the
structures determined; a recent report describing the highly sought after ternary complex of
the Wnt pathway proteins, R-spondin 1, RNF43 and LGR5, highlights this point [4].

By far the greatest demand for recombinant mammalian proteins is for therapeutic
development and applications. The production of recombinant proteins for
biopharmaceutical use is a multi-billion dollar industry, with global sales over US$120
billion per year and an anticipated increase to US$150 billion by 2015 [5]. Of the top nine
classes of biologic drugs sold in 2011, monoclonal antibodies (mAbs) command the highest
sales (Figure 1) and this trend is growing [6].

While Escherichia coli (E. coli), yeast and insect cell lines are still the preferred platforms
for many protein expression groups, mammalian proteins often require mammalian cells for
optimum yields and activity. While a wide range of platforms have been successfully
exploited for laboratory use, the bulk of recent biologics have been produced in mammalian
cell lines due to the requirement for post translational modification and the biosynthetic
complexity of the target proteins [1]. In the case of monoclonal antibodies, Chinese Hamster
NIH-PA Author Manuscript

Ovary (CHO) and NS0 (mouse myeloma) cells are the most commonly used lines [7,8].
With the substantial growth being realized in the area of biologics, there is a continuing
demand for new and enhanced mammalian expression platforms. The goal of this review is
to highlight the range of mammalian platforms available for recombinant protein production
as well as advances in technologies for the rapid and efficient selection of highly productive
clones.

Expression platforms
CHO
The workhorse of mammalian protein production (especially at industrial scale) is the CHO
cell line, isolated by Theodore Puck in the late 1950’s [9]. Initially selected for radiation
cytogenetic studies due to their low chromosome number (2n = 22), CHO cells have proven
to be a hardy and reliable cell line in culture. Since the commercial introduction of human
tissue plasminogen activator (tPA) as the first recombinant therapeutic protein produced
from mammalian cells [10], the annual global revenue of products from CHO cells has
increased to more than US$100 billion and continues to grow [11]. The wide spread success
of the CHO platform is due to its unparalleled adaptability allowing for growth of these cells
NIH-PA Author Manuscript

at high densities in suspension cultures and ease of adaptation to serum free conditions.
There has been a great deal of improvement in the quality and availability of chemically
defined, serum free media that is devoid of animal-derived materials. These tailored media
are more cost effective, as they do not require supplementation with fetal calf serum; safer,
as there is less risk of viral and prion contamination from bovine serum; and have simplified
downstream processing requirements, as they contain fewer protein contaminants. In
addition, a study in 1989 tested 44 human pathogens (including human immunodeficiency
virus (HIV), influenza, polio, herpes and measles), and found the majority of them do not
replicate in CHO cells, thus making CHOs ideal from a regulatory standpoint [12].
However, the adaptability of the CHO line also has its drawbacks, as each production target
requires the selection of clones that exhibit the necessary phenotypic properties, including
product quality/uniformity, doubling time and long term viability, under bioprocess
conditions. Even when an appropriate CHO production clone has been identified,

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 3

phenotypic drift (i.e. changes in the previously selected characteristics) is not uncommon
and remains a challenge [13].
NIH-PA Author Manuscript

While enhancing clonal stability (i.e. product uniformity) is an area of intense study, the
most significant improvements to CHO culture have resulted from the optimization of
media, feeding strategies and downstream processing. These improvements have resulted in
yields ranging between 2–6 g/L for antibody products [14]. A particular focus of product
optimization in CHO cells is glycosylation, as it has been shown that variation in
glycosylation patterns affects product stability and function, and non-natural glycoforms can
be immunogenic [15–17]. This is particularly true of the terminal galactose-α-1,3-galactose
(α-Gal) epitope, which has been demonstrated to be added to proteins produced in murine
cell lines, and is capable of inducing an immune response in humans [18]. The importance
of glycoform profiles in therapeutics has been highlighted by the adverse clinical effects
associated with an induced IgE-mediated anaphylaxis response in patients treated with the
commercial antibody Erbitux (cetuximab), which was manufactured in a murine myeloma
cell line and possessed α-Gal epitopes [18,19]. It was thought that CHO cells lacked the
biosynthetic machinery to produce the α-Gal epitope, but this assumption has been brought
into question by reports that CHO cells can add the α-Gal antigen to recombinant products,
as has been observed for Orencia (abatacept) [18]. Therefore, it is essential that CHO
production clones be carefully monitored for product uniformity and safety in terms of
glycosylation profiles.
NIH-PA Author Manuscript

The genomic variability of CHO cells and the fact that they are functionally hemizygous for
many genes [20,21] also has certain advantages, as it has allowed for the isolation of mutant
lines with deficiencies in metabolic enzymes. These mutants are dependent on certain
nutrients for survival, making them ideal for the generation of producer lines by using the
deficiency as a selection marker. Mutants of the enzyme dihydrofolate reductase (DHFR)
were generated in this manner [22] and will be discussed below. To support further
development of CHOs for protein production, a genome sequencing project was initiated in
2002 as a collaboration between the University of Minnesota and the Bioprocessing
Technology Institute of Singapore (A*STAR). This collaboration led to two cDNA libraries
being constructed from three CHO cell lines, grown under different conditions,
corresponding to over 4,000 expressed sequence tags (ESTs) [23]. This initial study led to
further sequencing efforts under the auspices of the Consortium on Chinese Hamster Ovary
Cell Genomics in partnership with the Society for Biological Engineers (SBE), with the goal
being the identification of genetic markers associated with high productivity [12].

While there is no doubt that CHO cells will continue to be used and developed for
biopharmaceutical production, the push for generating more complex human proteins, with a
NIH-PA Author Manuscript

better safety profile, has led to the further development of existing lines and the generation
of novel human cell lines that we believe will be the platforms of the future.

HEK 293
Developed almost two decades after the CHO cell line, the 293 cell line was the first human
line to be transformed using sheared adenovirus DNA fragments of the Ad5 serotype [24].
Transformation of the human embryonic kidney (HEK) cells by viral DNA was performed
with a calcium transfection technique developed by Graham and van der Eb [25,26]. Since
its development, the 293 cell line has become one of the most commonly used human cell
lines for protein production. There have been many variants of the original line, such as
293N3S developed for suspension growth in bioreactors for adenovirus production [27] and
the 293S line that was adapted to grow under serum free conditions [28]. In order to improve
transient gene expression (discussed below), two additional lines were developed, the 293-T
line expressing the SV40 large T-antigen [29] and the 293-E line expressing the Epstein-

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 4

Barr virus EBNA1 protein [30]. The latter two lines support the episomal replication of
plasmids containing either the SV40 origin of replication or the EBV oriP, respectively,
thereby prolonging the expression of the target gene after transient transfection. While CHO
NIH-PA Author Manuscript

cells have been the workhorse of recombinant protein production, the 293 line has grown in
prominence with the realization that proteins produced in HEK cells are a closer match to
naturally occurring human proteins in terms of post translational modification and function
[31]. Improvements in culture processes has resulted in 293-based platforms capable of
supporting antibody yields exceeding 1 g/L [32]. More recently the HKB11 line has been
developed which is a hybrid between the HEK 293S line and a human B cell line, 2B8
(derived from a Burkitt’s lymphoma line) [33]. This line combines features of the parental
lines, resulting in a system that is easy to transfect (a characteristic of 293s), with the
capacity to secrete large amounts of protein (a characteristic of B cells). It’s utility has been
amply demonstrated in the case of human coagulation factor VIII (which contains 25
potential N-linked glycosylation sites, 6 tyrosine sulfation sites and 7 disulfide bonds) with
yields that are about 8-fold higher than the parental 293 line [34].

PER.C6
The PER.C6 (Crucell) line was originally generated from human retinoblast cells
immortalized by transfection with an E1 minigene for the cost-effective production of safe,
clinical-grade recombinant adenovirus vectors [35]. However this cell line also has several
features that make it ideal for recombinant protein production: PER.C6 were generated in
NIH-PA Author Manuscript

compliance with Good Laboratory Practice and has been extensively documented, the cell
banks meet all pertinent United States and European Economic Community regulatory
requirements and importantly (from a production standpoint), they can be grown in
suspension to high cell densities (up to 1X107 cells/ml) in serum-free medium. These cells
were shown to readily produce 300–500 mg/L of IgG without any media or feed
optimization [36].

CAP/CAP-T
Similar to the PER.C6 line, CEVEC’s Amniocyte Production (CAP) cell line was originally
developed for adenovirus production by transforming primary human amniocytes (obtained
transabdominally by amniocentesis) using the E1 functions of Ad5 [37]. A variant of this
line, CAP-T, was generated which constitutively expresses the SV40 large T antigen in
order to make them suitable as a host for transient gene expression using plasmids carrying
the SV40 ori; this line is capable of expressing and secreting previously difficult-to-express
protein targets [38]. It is hypothesized that the stem cell-like origin of CAP cells may lead to
a different or larger repertoire of processing enzymes and chaperones compared to more
differentiated production cell lines. This hypothesis is supported by the example of the bone
NIH-PA Author Manuscript

morphogenetic protein (BMP) antagonist protein which failed to be secreted from HEK 293
cells (where it was located in the insoluble fraction) but was successfully secreted into the
medium by CAP cells. The yields of a few other test proteins (secreted embryonic alkaline
phosphatase, SEAP and a kinase receptor extracellular domain) seem to indicate that the
CAP-T cells are at least as good as the HEK 293-E cells, if not a little better, and superior to
CHO cells [38].

Advances in gene delivery/integration

Transient transfection followed by drug selection has been the traditional method for DNA
delivery and integration for creating producer lines. While successful, this is often a slow
(4–6 months) and tedious process and the last decade has seen an increase in novel and
sophisticated approaches for enhancing the efficiency of delivery and reducing the timeline
for obtaining a producer cell line (Figure 2).

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 5

Transient gene expression (TGE)

One strategy to accelerate the protein production process is to eliminate the drug selection
step by performing transient transfections at scale. Using this approach, clonal cell lines are
NIH-PA Author Manuscript

not necessary as cells are directly cultured (and transfected) at the production scale and
therefore do not need to be cultivated for long periods of time. The use of suspension
adapted HEK and CHO lines, along with optimized commercial media, as well as the use of
inexpensive transfection agents (such as calcium phosphate and polyethylenimine, PEI) has
made large scale transient transfection an attractive and successful approach (reviewed in
[39,40]). Transfection at scale implies culture volumes ranging from several hundred
milliliters in shake flasks or square bottles [41] to several hundred liters in stirred tank
bioreactors, orbital shakers [42] or Wave™ reactors [43].

One of the drawbacks of this approach is the need for multi-milligram quantities of
recombinant plasmid DNA; however, obtaining decigram quantities of plasmid DNA from a
few liters of E. coli is fairly routine [39]. It should be noted that the quality of the DNA used
for transfection can be an important factor; while the quality may not be of critical
importance for most TGE experiments, it can be essential for the production of clinical
grade proteins where endotoxin and other contaminants need to be minimized or eliminated
[44,45].

As for the transfection reagent, 25 kDa linear PEI is the most commonly used in TGE
NIH-PA Author Manuscript

approaches and has a long and successful track record [46–48]. While most transfections are
performed at cell densities of 1X105–1X106 cells/ml, recent reports have shown enhanced
production with high density transfection. For example, CHO cells transfected at 4X106
cells/ml produced up to 250 mg of antibody at scale in 14 days [49] and HEK 293 cells
transfected at densities as high as 2X107 cells/ml resulted in a doubling of product titer [50].
Of note, the latter study involved direct transfection, in which DNA and PEI were added
directly to the culture without a priori complex formation, resulting in improved ease of
handling and reduced transfection variability.

Once a transient production cell line has been established, several strategies are available for
maximizing protein expression. These approaches, while useful in stable producer lines, are
especially important in a transient setting where the culture period is generally limited to
10–14 days. One method involves the over-expression of anti-apoptotic proteins, such as
bcl-2 family members [51–53] and Bcl-x(L) [54,55], which leads to higher viability and
improved yields. Another approach is to induce cell cycle arrest thereby improving
productivity; this strategy can be accomplished either chemically using anti-mitotic agents
(such as hydroxyurea, nocodazole, colchicine, paclitaxel or vinblastine) [56] or genetically
by targeting cell cycle inhibitors such as p18, p21 or p27Kip1 [39]. Growth factors such as
NIH-PA Author Manuscript

acidic Fibroblast Growth Factor (aFGF) or recombinant insulin-like growth factor (LR3-
IGF) can also increase cell densities and improve yield. DNA methyltransferase inhibitors
and histone deacetylase inhibitors such as valproic acid and sodium butyrate have also been
shown to improve recombinant protein yields in transient settings [57]. Ultimately, a
combination of factors may be necessary to achieve the desired enhancement, such as those
utilized in the ‘XLG protocol’ that involves over-expression of p18 and p21, expression of
aFGF and addition of Valproic Acid. These modifications result in antibody production that
exceeds 1 g/L in HEK 293-E cells, a 27-fold improvement over standard approaches [32].

Recombinase Mediated Cassette Exchange (RMCE)

Integration of exogenous DNA into a host chromosome is for the most part a random event.
As a result, most integrations are unproductive as only a small proportion of a cell’s genome
(~0.1%) is actively transcribed. Therefore, if the recombinant construct can be targeted to an

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 6

active and stable region (hotspot) of the genome then even a single integration at such a
favorable site can lead to higher production yields than multiple integrations at sub-optimal
regions of the genome [58]. This idea led to the development of RMCE, initially as a means
NIH-PA Author Manuscript

of developing transgenic mouse models (reviewed in [59]), but more recently for the
generation of stable producer lines for recombinant proteins. In brief, this strategy involves
the development of a master cell line that contains a single integration of a reporter gene at a
hotspot flanked by integration target sequences such as Flp recognition target sites (FRT) or
loxp sites (for the Cre system). The gene of interest can then be introduced into this line in
the presence of the appropriate recombinase leading to the exchange of the reporter gene
with the target gene, “Flp-out” or “Cre-out” [60]. The use of adeno- or non-integrating
lentivirus has also been shown to facilitate this reaction [61,62]. While this system promises
to improve the speed and efficiency with which producer lines can be generated, the actual
improvement in yields reported to date has only been moderate [63].

Viral delivery
Lentiviral vectors (LVs) derived from human immunodeficiency virus type-1 (HIV-1) have
a long history of efficient gene delivery in gene therapy applications [64]. Given the
efficiency with which LVs are capable of transducing a broad range of cell types, it is not
surprising that LVs have been recently used as a gene delivery tool for protein production.
The ‘Daedalus’ system has shown promising results for the rapid generation of stable
producer lines in HEK 293 Freestyle cells (Invitrogen), with yields of 20–100 mg/L reported
NIH-PA Author Manuscript

for a variety of secreted proteins without the need for clonal selection [65]. LVs have also
been used in the CHO platform where certain clones were shown to produce as much as 200
mg/L of the human tumor necrosis factor receptor-Fc fusion protein [66]. One of the
drawbacks of the LV system is the modest packaging size of the lentivirus capsid (~10
kilobases), which may limit the maximum size of the recombinant protein being expressed.

Enhancement of protein production using UCOE, SAR and MAR elements

Major factors contributing to the loss of productivity over time are the positional effects that
an integrated gene experiences in the context of the host genome. To overcome the effects of
silencing and the associated loss in protein yield, several new locus control elements have
been developed, including scaffold or matrix attachment regions (S/MARs) and Ubiquitous
Chromatin Opening Elements (UCOEs) [67]. S/MARs are DNA sequences which serve as
attachment points to the nuclear matrix, thus maintaining a transcriptionally active
chromatin structure. These sequences have also been shown to enhance DNA demethylation,
making genes more accessible to the transcriptional machinery [68,69]. MARs have also
been shown to serve as binding sites for transcription factors like CCCTC binding factor
(CTCF) and nuclear matrix proteins (NMP) that enhance gene expression [70–72]. The β-
NIH-PA Author Manuscript

interferon SAR, human β-globin MAR and chicken lysozyme MAR have been shown to
promote stable protein expression (as long as 6 months) and increase the occurrence of high
producing clones, thereby reducing the need for clonal selection [73–76].

UCOEs (Merck Millipore) are methylation-free CpG-rich sequences that help maintain
chromatin in an ‘open’ conformation, resulting in significantly reduced silencing. These
sequences enhance protein expression over extended periods of time in in vitro transfection
experiments [77,78], as well as in gene therapy settings [79,80]. While effective UCOE
elements tend to be in the 2–4 kb range, it is notable that the Daedalus system uses the
smallest UCOE sequence described to date (0.7 kb), with activity that is equivalent to the
larger fragments [65]. The use of UCOEs in producer line development has shown a 3–6
fold improvement in protein yield over several months of culture [65,81].

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 7

Advances in selection methodology

The traditional methods of integration followed by drug selection for generating stable
NIH-PA Author Manuscript

producer lines can be tedious and time consuming, often taking several months. Further,
increasing the dose of selection agent in order to select for higher producing clones can lead
to a loss of successful clones due to the slower growth of these cells at high drug
concentration. As a result, there have been considerable efforts to increase the speed and
efficiency of selection methods and to enhance the final producer yields.

Destabilized selection markers

An attractive alternative to increasing selection pressure by increasing the concentration of
the drug is to attenuate the activity of the selection marker so that high producer lines are
still efficiently selected at lower doses of the drug. The hope is to reduce the undesirable
side-effects of the drug (e.g. slow cell growth) while maintaining sufficient selection
pressure to obtain highly producing clones. This strategy is exemplified by the introduction
of mutations into the neomycin phosphotransferase II selection marker (Neo), which results
in reduced affinity for the selection drug neomycin. This approach led to an improvement in
monoclonal antibody production from between 6 to 17 fold [67,82,83]. Alternatively,
mutation of the Neo selection gene can be avoided by placing the gene under the control of a
weak promoter (Herpes simplex virus thymidine kinase), which reduces transcription and
availability of Neo [84]. Another approach is to re-engineer the resistance sequence to
NIH-PA Author Manuscript

contain the least preferred codons of the host organism (i.e., ‘de-optimization’) in order to
lower translational efficiency and reduce the cellular concentration of the resistance protein
(e.g., dihydrofolate reductase; DHFR) [85].

One of the most popular selection systems in current use is methotrexate (MTX)
amplification with DHFR-deficient CHO cells [12,14,63,67,86]. The DHFR-deficient CHO
cells (CHO-DG44) were created by gamma-ray induced mutation of CHO cells and require
the presence of glycine, hypoxanthine and thymidine to survive [22,87]. Once the cells are
transfected with the gene of interest (linked to the DHFR selection gene), hypoxanthine and
thymidine are withdrawn from the culture medium to select for the successful transfectants.
Further selection pressure is introduced by the addition of MTX to the culture which acts as
a competitive inhibitor of DHFR and promotes MTX amplification, selecting for cells with
higher copy numbers (and therefore productivity) of the DHFR gene and associated target
gene [88]. In order to weaken the selection marker, and therefore increase stringency, Yap
and colleagues investigated destabilizing the mRNA, as well as the DHFR protein [89].
Their strategy was to introduce short AU rich elements (AREs) into the mRNA which
constitutively destabilizes the mRNA. In a further modification, the murine ornithine
decarboxylase (MODC) PEST sequence was added to the dhfr gene, resulting in higher
NIH-PA Author Manuscript

turnover of the protein. The authors tested this strategy with the expression of interferon
gamma (IFNγ) and found that 1.7-, 6.6- and 13.3-fold improvements in specific IFNγ
productivities were obtained with the application of ARE, MODC PEST, and both ARE and
MODC PEST, respectively. In an attempt to more closely link the gene of interest and
selection marker (thereby preventing the possibility of gene fragmentation and loss of the
target gene), Lam and colleagues introduced the dhfr gene directly downstream of the gene
of interest using an Internal Ribosome Entry Sequence (IRES) [90]. This strategy allowed
for both genes to be translated off of the same RNA; in addition, the stringency of selection
was further increased by adding the PEST sequence to the dhfr gene.

The glutamine synthetase (GS) system is another method of gene amplification, which has
been successfully used with GS-negative NS0 cells [91], as well as GS-expressing CHO
cells [92]. The CHO cells, containing an endogenous GS gene, need to be treated with the
GS enzyme inhibitor methionine sulfoximine (MSX) to suppress the activity of endogenous

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 8

GS. Increasing levels of MSX can then be used to select for clones with a high copy number
of the selection gene and flanking target gene. This method has been used to drive target
gene copy number in CHO cells to as many as 200 copies [93]. A fortuitous advantage of
NIH-PA Author Manuscript

this system is that these cells do not require glutamine supplementation in the media, and as
a result the culture does not accumulate high levels of toxic ammonia. The GS system has
been recently enhanced with the development of a GS-knockout CHO line (CHOK1SV) that
led to a significant increase in selection stringency and a six-fold improvement in the
efficiency of identifying similar numbers of highly productive cell lines (compared to the
standard protocol) for a given recombinant monoclonal antibody [94].

Fluorescence-Activated Cell Sorting (FACS)-Based Screening

Flow cytometry is a powerful technology that allows for the rapid, objective and sensitive
multiparametric analysis of cells [95]. In addition to its analytical capabilities, flow
cytometry also allows for the separation of the analyzed cells. In a flow cytometer cells pass
in a single stream, one by one, in front of a laser. The laser then interrogates the stream of
cells for different morphologic, structural and fluorescent properties of the cell. At present as
many as a dozen or more of these characteristics can be acquired for each cell passing
through the cytometer, providing a wealth of information regarding the health and various
other user-defined parameters of each cell. While most cytometers are devoted solely to
analysis, many can also sort cells based on characteristics that the user would like to obtain,
making the sorting of transfection positive cells (detected by an associated fluorescent
NIH-PA Author Manuscript

reporter) routine. Recently, high-throughput cytometers, such as the HyperCyt (Intellicyt),

have dramatically increased the speed with which cell populations can be interrogated for
user-defined characteristics [96,97]. Flow cytometers can be used to sort cells at the single-
cell level, depositing ~1 cell/well of a 96-well plate, or can be used for bulk sorting, such as
the top 10% of Green Fluorescent Protein reporter positive cells; allowing for the creation of
clonal or oligoclonal populations in a matter of hours.

A non-invasive technique termed ‘cold capture’ has recently been developed to detect the
amount of recombinant protein being secreted by a producer line. In this approach cells are
incubated on ice (4 °C) to slow the secretion process and a fluorescent antibody is used for
the FACS-based detection of recombinant proteins ‘trapped’ on the cell surface [98]. The
top FACS-isolated clones can show a five- to seven-fold increase in yield. Further work
showed that the same process can be performed at room temperature (21 °C) and that use of
phycoerythrin (PE) as a fluorophore for detecting the secreted protein was superior to
fluorescein isothiocyanate (FITC) in terms of stability of the signal [99].

An alternate non-invasive strategy is the use of FITC-labeled methotrexate (F-MTX) to bind

an intracellular DHFR selection marker [100]. This strategy allowed for the rapid isolation
NIH-PA Author Manuscript

of gene amplified cells from a heterogeneous pool.

Summary
Given the rapid pace at which new cell lines, media formulations, gene delivery and clonal
selection techniques are emerging, the production of proteins for basic research and
pharmaceutical use will continue to benefit from enhanced efficiencies and reduced costs.
While transient transfection has experienced a revival due to optimization of large scale and
high density transfection techniques, alternate methods of gene delivery such as RMCE and
viral platforms have increased the options available. When combined with sophisticated
selection methods, these approaches readily enable the screening of large numbers of target
variants for expression or the production of gram quantities of a therapeutic target. The
advent of novel human production cell lines continues to push the boundaries of the targets
that can be expressed, their quality and total yields. It would not be surprising if the reliance

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 9

on CHO cells for therapeutic production starts to wane as pharmaceutical companies invest
in and embrace these new cell lines; it is estimated that there are already more than a dozen
PER.C6-based products in Phase I/II clinical trials [101].
NIH-PA Author Manuscript

Despite the increasing number of protein production platforms available for use, there is no
‘magic bullet’ capable of meeting all challenges. The idiosyncratic behavior of each protein
and the eventual downstream applications, along with cost and ease of use, drive the
decision towards one platform or another. The large-scale NYSGRC structure and function
discovery program uses a combination of platforms (E. coli, insect and mammalian cells) to
produce target proteins. While most groups cannot or will not take such a broad approach to
protein production, the options within a given platform are continuously expanding.
Therefore, a limitation of protein production, at the moment, seems to be associated with the
complexity of targets that can be imagined rather than production techniques available.

Acknowledgments
This work was supported by National Institutes of Health (NIH) Grants GM094662, GM094665 and CA013330.

References
1. Zhu J. Mammalian cell protein expression for biopharmaceutical production. Biotechnol. Adv.
NIH-PA Author Manuscript

2012; 30:1158–1170. [PubMed: 21968146]

2. Almo SC, Garforth SJ, Hillerich BS, Love JD, Seidel RD, Burley SK. Protein production from the
structural genomics perspective: achievements and future needs. Curr. Opin. Struct. Biol. 2013:1–
10. [PubMed: 23374590]
3. Savitsky P, Bray J, Cooper CDO, Marsden BD, Mahajan P, Burgess-Brown N a, Gileadi O.
Highthroughput production of human proteins for crystallization: the SGC experience. J. Struct.
Biol. 2010; 172:3–13. [PubMed: 20541610]
4. Chen P-H, Chen X, Lin Z, Fang D, He X. The structural basis of R-spondin recognition by LGR5
and RNF43. Genes Dev. 2013:1345–1350. [PubMed: 23756651]
5. Butler M, Meneses-Acosta a. Recent advances in technology supporting biopharmaceutical
production from mammalian cells. Appl. Microbiol. Biotechnol. 2012; 96:885–894. [PubMed:
23053101]
6. Aggarwal SR. What’s fueling the biotech engine-2011 to 2012. Nat. Biotechnol. 2012; 30:1191–
1197. [PubMed: 23222785]
7. Birch JR, Onakunle Y. Biopharmaceutical proteins: opportunities and challenges. Methods Mol.
Biol. 2005; 308:1–16. [PubMed: 16082021]
8. Chu L, Robinson DK. Industrial choices for protein production by large-scale cell culture. Curr.
Opin. Biotechnol. 2001:180–187. [PubMed: 11287235]
NIH-PA Author Manuscript

9. Puck T, Cieciura S, Robinson A. Genetics of somatic mammalian cells III. Long-term cultivation of
euploid cells from human and animal subjects. J. Exp. Med. 1958
10. Deschênes I, Finkle CD, Winocour PD. Effective use of BCH-2763, a new potent injectable direct
thrombin inhibitor, in combination with tissue plasminogen activator (tPA) in a rat arterial
thrombolysis model. Thromb. Haemost. 1998; 80:186–191. [PubMed: 9684808]
11. Jadhav V, Hackl M, Druz A, Shridhar S, Chung C-Y, Heffner KM, Kreil DP, Betenbaugh M,
Shiloach J, Barron N, Grillari J, Borth N. CHO microRNA engineering is growing up: Recent
successes and future challenges. Biotechnol. Adv. 2013
12. Jayapal K, Wlaschin K. Recombinant protein therapeutics from CHO cells-20 years and counting.
Chem. Eng. Prog. 2007; 103:40–47.
13. Jadhav V, Hackl M, Druz A, Shridhar S, Chung C-Y, Heffner KM, Kreil DP, Betenbaugh M,
Shiloach J, Barron N, Grillari J, Borth N. CHO microRNA engineering is growing up: Recent
successes and future challenges. Biotechnol. Adv. 2013
14. Wurm FM. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat.
Biotechnol. 2004; 22:1393–1398. [PubMed: 15529164]

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 10

15. Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics. Nat. Rev. Drug
Discov. 2009; 8:226–234. [PubMed: 19247305]
16. Beck A, Wagner-Rousset E. Trends in glycosylation, glycoanalysis and glycoengineering of
NIH-PA Author Manuscript

therapeutic antibodies and Fc-fusion proteins. Curr. Pharm. Biotechnol. 2008; 9:482–501.
[PubMed: 19075687]
17. Costa AR, Rodrigues ME, Henriques M, Oliveira R, Azeredo J. Glycosylation: impact, control and
improvement during therapeutic protein production. Crit. Rev. Biotechnol. 2013; 8551:1–19.
18. Bosques CJ, Collins BE, Meador JW, Sarvaiya H, Murphy JL, Dellorusso G, Bulik D a, Hsu I-H,
Washburn N, Sipsey SF, Myette JR, Raman R, Shriver Z, Sasisekharan R, Venkataraman G.
Chinese hamster ovary cells can produce galactose-α-1,3-galactose antigens on proteins. Nat.
Biotechnol. 2010; 28:1153–1156. [PubMed: 21057479]
19. Arnold DF, Misbah S a. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha- 1,3-
galactose. N. EnglJMed. 2008; 358:2735. author reply 2735-6.
20. Chasin LA, Urlaub G. Chromosome-wide event accompanies the expression of recessive mutations
in tetraploid cells. Science. 1975; 187:1091–1093. [PubMed: 1167702]
21. Simon AE, Taylor MW, Bradley WE, Thompson LH. Model involving gene inactivation in the
generation of autosomal recessive mutants in mammalian cells in culture. Mol. Cell. Biol. 1982;
2:1126–1133. [PubMed: 6891022]
22. Urlaub G, Chasin L a. Isolation of Chinese hamster cell mutants deficient in dihydrofolate
reductase activity. Proc. Natl. Acad. SciUSA. 1980; 77:4216–4220.
23. Wlaschin KF, Nissom PM, Gatti M, de L, Ong PF, Arleen S, Tan KS, Rink A, Cham B, Wong K,
NIH-PA Author Manuscript

Yap M, Hu W-S. EST sequencing for gene discovery in Chinese hamster ovary cells. Biotechnol.
Bioeng. 2005; 91:592–606. [PubMed: 16003777]
24. Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by
DNA from human adenovirus type 5. J. Gen. Virol. 1977; 36:59–74. [PubMed: 886304]
25. Graham FL, van der Eb AJ. Transformation of rat cells by DNA of human adenovirus 5. Virology.
1973; 54:536–539. [PubMed: 4737663]
26. Graham FL, van der Eb AJ. A new technique for the assay of infectivity of human adenovirus 5
DNA. Virology. 1973; 52:456–467. [PubMed: 4705382]
27. Graham FL. Growth of 293 cells in suspension culture. J. Gen. Virol. 1987; 68(Pt 3):937–940.
[PubMed: 3819703]
28. Garnier A, Côté J, Nadeau I, Kamen A, Massie B. Scale-up of the adenovirus expression system
for the production of recombinant protein in human 293S cells. Cytotechnology. 1994; 15:145–
155. [PubMed: 7765926]
29. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, Calos MP. Analysis of mutation in human
cells by using an Epstein-Barr virus shuttle system. Mol. Cell. Biol. 1987; 7:379–387. [PubMed:
3031469]
30. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production
by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res.
NIH-PA Author Manuscript

2002; 30:e9. [PubMed: 11788735]

31. Walsh G. Post-translational modifications of protein biopharmaceuticals. Drug Discov. Today.
2010; 15:773–780. [PubMed: 20599624]
32. Backliwal G, Hildinger M, Chenuet S, Wulhfard S, De Jesus M, Wurm FM. Rational vector design
and multi-pathway modulation of HEK 293E cells yield recombinant antibody titers exceeding 1
g/l by transient transfection under serum-free conditions. Nucleic Acids Res. 2008; 36:e96.
[PubMed: 18617574]
33. Cho MS, Yee H, Chan S. Establishment of a human somatic hybrid cell line for recombinant
protein production. J. Biomed. Sci. 2002; 9:631–638. [PubMed: 12432229]
34. Mei B, Chen Y, Chen J, Pan CQ, Murphy JE. Expression of human coagulation factor VIII in a
human hybrid cell line, HKB11. Mol. Biotechnol. 2006; 34:165–178. [PubMed: 17172662]
35. Fallaux F, Bout A. New helper cells and matched early region 1-deleted adenovirus vectors prevent
generation of replication-competent adenoviruses. Hum. Gene Ther. 1998; 9:1909–1917.
[PubMed: 9741429]

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 11

36. Jones D, Kroos N, Anema R, van Montfort B, Vooys A, van der Kraats S, van der Helm E, Smits
S, Schouten J, Brouwer K, Lagerwerf F, van Berkel P, Opstelten D-J, Logtenberg T, Bout A.
High-level expression of recombinant IgG in the human cell line per.c6. Biotechnol. Prog. 2003;
NIH-PA Author Manuscript

19:163–168. [PubMed: 12573020]

37. Schiedner G, Hertel S, Kochanek S. Efficient transformation of primary human amniocytes by E1
functions of Ad5: generation of new cell lines for adenoviral vector production. Hum. Gene Ther.
2000; 11:2105–2116. [PubMed: 11044912]
38. Fischer S, Charara N, Gerber A, Wölfel J, Schiedner G, Voedisch B, Geisse S. Transient
recombinant protein expression in a human amniocyte cell line: the CAP-T® cell system.
Biotechnol. Bioeng. 2012; 109:2250–2261. [PubMed: 22488157]
39. Geisse S. Reflections on more than 10 years of TGE approaches. Protein Expr. Purif. 2009; 64:99–
107. [PubMed: 19027070]
40. Baldi L, Hacker DL, Adam M, Wurm FM. Recombinant protein production by large-scale
transient gene expression in mammalian cells: state of the art and future perspectives. Biotechnol.
Lett. 2007; 29:677–684. [PubMed: 17235486]
41. Muller N, Girard P, Hacker DL, Jordan M, Wurm FM. Orbital shaker technology for the
cultivation of mammalian cells in suspension. Biotechnol. Bioeng. 2005; 89:400–406. [PubMed:
15619325]
42. Zhang X, Stettler M, Reif O, Kocourek A, Dejesus M, Hacker DL, Wurm FM. Shaken helical track
bioreactors: Providing oxygen to high-density cultures of mammalian cells at volumes up to 1000
L by surface aeration with air. N. Biotechnol. 2008; 25:68–75. [PubMed: 18504021]
NIH-PA Author Manuscript

43. Geisse S, Henke M. Large-scale transient transfection of mammalian cells: a newly emerging
attractive option for recombinant protein production. J. Struct. Funct. Genomics. 2005; 6:165–170.
[PubMed: 16211514]
44. Schmid G, Schlaeger EJ, Wipf B. Non-GMP plasmid production for transient transfection in
bioreactors. Cytotechnology. 2001; 35:157–164. [PubMed: 22358854]
45. Rozkov A, Larsson B, Gillström S, Björnestedt R, Schmidt SR. Large-scale production of
endotoxin-free plasmids for transient expression in mammalian cell culture. Biotechnol. Bioeng.
2008; 99:557–566. [PubMed: 17680665]
46. Haldankar R, Li D, Saremi Z, Baikalov C, Deshpande R. Serum-free suspension large-scale
transient transfection of CHO cells in WAVE bioreactors. Mol. Biotechnol. 2006; 34:191–199.
[PubMed: 17172664]
47. Geisse S, Jordan M, Wurm FM. Large-scale transient expression of therapeutic proteins in
mammalian cells. Methods Mol. Biol. 2005; 308:87–98. [PubMed: 16082028]
48. Liu C, Dalby B, Chen W, Kilzer JM, Chiou HC. Transient transfection factors for high-level
recombinant protein production in suspension cultured mammalian cells. Mol. Biotechnol. 2008;
39:141–153. [PubMed: 18327552]
49. Rajendra Y, Kiseljak D, Baldi L, Hacker DL, Wurm FM. A simple high-yielding process for
transient gene expression in CHO cells. J. Biotechnol. 2011; 153:22–26. [PubMed: 21392548]
50. Backliwal G, Hildinger M, Hasija V. High-density transfection with HEK-293 cells allows
NIH-PA Author Manuscript

doubling of transient titers and removes need for a priori DNA complex formation with PEI.
Biotechnol. 2008; 99:721–727.
51. Figueroa B, Sauerwald TM, Mastrangelo a J, Hardwick JM, Betenbaugh MJ. Comparison of Bcl-2
to a Bcl-2 deletion mutant for mammalian cells exposed to culture insults. Biotechnol. Bioeng.
2001; 73:211–222. [PubMed: 11257603]
52. Tey BT, Singh RP, Piredda L, Piacentini M, Al-Rubeai M. Influence of bcl-2 on cell death during
the cultivation of a Chinese hamster ovary cell line expressing a chimeric antibody. Biotechnol.
Bioeng. 2000; 68:31–43. [PubMed: 10699869]
53. Kim NS, Lee GM. Response of recombinant Chinese hamster ovary cells to hyperosmotic
pressure: effect of Bcl-2 overexpression. J. Biotechnol. 2002; 95:237–248. [PubMed: 12007864]
54. Majors BS, Betenbaugh MJ, Pederson NE, Chiang GG. Enhancement of transient gene expression
and culture viability using Chinese hamster ovary cells overexpressing Bcl-x(L). Biotechnol.
Bioeng. 2008; 101:567–578. [PubMed: 18727128]

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 12

55. Lee SK, Lee GM. Development of apoptosis-resistant dihydrofolate reductase-deficient Chinese
hamster ovary cell line. Biotechnol. Bioeng. 2003; 82:872–876. [PubMed: 12701155]
56. Tait AS, Brown CJ, Galbraith DJ, Hines MJ, Hoare M, Birch JR, James DC. Transient production
NIH-PA Author Manuscript

of recombinant proteins by Chinese hamster ovary cells using polyethyleneimine/DNA complexes

in combination with microtubule disrupting anti-mitotic agents. Biotechnol. Bioeng. 2004;
88:707–721. [PubMed: 15532040]
57. Geisse S. Transient expression technologies: past, present, and future. Methods Mol. Biol. (Clifton,
NJ). 2012; 899
58. Wirth M, Bode J, Zettlmeissl G, Hauser H. Isolation of overproducing recombinant mammalian
cell lines by a fast and simple selection procedure. Gene. 1988; 73:419–426. [PubMed: 3072266]
59. Turan S, Galla M, Ernst E, Qiao J, Voelkel C, Schiedlmeier B, Zehe C, Bode J.
Recombinasemediated cassette exchange (RMCE): traditional concepts and current challenges. J.
Mol. Biol. 2011; 407:193–221. [PubMed: 21241707]
60. Turan S, Kuehle J, Schambach A, Baum C, Bode J. Multiplexing RMCE: versatile extensions of
the Flp-recombinase-mediated cassette-exchange technology. J. Mol. Biol. 2010; 402:52–69.
[PubMed: 20650281]
61. Sorrell, D a; Robinson, CJ.; Smith, J-A.; Kolb, AF. Recombinase mediated cassette exchange into
genomic targets using an adenovirus vector. Nucleic Acids Res. 2010; 38:e123. [PubMed:
20371519]
62. Torres R, García A, Payá M, Ramirez JC. Non-integrative lentivirus drives high-frequency
cremediated cassette exchange in human cells. PLoS One. 2011; 6:e19794. [PubMed: 21625434]
NIH-PA Author Manuscript

63. Agrawal V. Strategies for Rapid Production of Therapeutic Proteins in Mammalian Cells.
Bioprocess Int. 2012; 10
64. Wiznerowicz M, Trono D. Harnessing HIV for therapy, basic research and biotechnology. Trends
Biotechnol. 2005; 23:42–47. [PubMed: 15629857]
65. Bandaranayake AD, Correnti C, Ryu BY, Brault M, Strong RK, Rawlings DJ. Daedalus: a robust,
turnkey platform for rapid production of decigram quantities of active recombinant proteins in
human cell lines using novel lentiviral vectors. Nucleic Acids Res. 2011; 39:e143. [PubMed:
21911364]
66. Oberbek A, Matasci M, Hacker DL, Wurm FM. Generation of stable, high-producing CHO cell
lines by lentiviral vector-mediated gene transfer in serum-free suspension culture. Biotechnol.
Bioeng. 2010; 41
67. Lai T, Yang Y, Ng S. Advances in Mammalian Cell Line Development Technologies for
Recombinant Protein Production. Pharmaceuticals. 2013; 6:579–603. [PubMed: 24276168]
68. Zhu B, Benjamin D, Zheng Y, Angliker H, Thiry S, Siegmann M, Jost JP. Overexpression of 5-
methylcytosine DNA glycosylase in human embryonic kidney cells EcR293 demethylates the
promoter of a hormone-regulated reporter gene. Proc. Natl. Acad. SciUSA. 2001; 98:5031–5036.
69. Jost JP, Oakeley EJ, Zhu B, Benjamin D, Thiry S, Siegmann M, Jost YC. 5-Methylcytosine DNA
glycosylase participates in the genome-wide loss of DNA methylation occurring during mouse
myoblast differentiation. Nucleic Acids Res. 2001; 29:4452–4461. [PubMed: 11691933]
NIH-PA Author Manuscript

70. Bidwell JP, Torrungruang K, Alvarez M, Rhodes SJ, Shah R, Jones DR, Charoonpatrapong K,
Hock JM, Watt AJ. Involvement of the nuclear matrix in the control of skeletal genes: the NMP1
(YY1), NMP2 (Cbfa1), and NMP4 (Nmp4/CIZ) transcription factors. Crit. Rev. Eukaryot. Gene
Expr. 2001; 11:279–297. [PubMed: 12067068]
71. Bell AC, West AG, Felsenfeld G. The protein CTCF is required for the enhancer blocking activity
of vertebrate insulators. Cell. 1999; 98:387–396. [PubMed: 10458613]
72. Girod P-A, Nguyen D-Q, Calabrese D, Puttini S, Grandjean M, Martinet D, Regamey A, Saugy D,
Beckmann JS, Bucher P, Mermod N. Genome-wide prediction of matrix attachment regions that
increase gene expression in mammalian cells. Nat. Methods. 2007; 4:747–753. [PubMed:
17676049]
73. Girod P-A, Zahn-Zabal M, Mermod N. Use of the chicken lysozyme 5’ matrix attachment region
to generate high producer CHO cell lines. Biotechnol. Bioeng. 2005; 91:1–11. [PubMed:
15889435]

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 13

74. Kim J, Do; Yoon, Y.; Hwang, H-Y.; Park, JS.; Yu, S.; Lee, J.; Baek, K.; Yoon, J. Efficient
selection of stable chinese hamster ovary (CHO) cell lines for expression of recombinant proteins
by using human interferon beta SAR element. Biotechnol. Prog. 21:933–937. [PubMed:
NIH-PA Author Manuscript

15932276]
75. Kim J-M, Kim J-S, Park D-H, Kang HS, Yoon J, Baek K, Yoon Y. Improved recombinant gene
expression in CHO cells using matrix attachment regions. J. Biotechnol. 2004; 107:95–105.
[PubMed: 14711493]
76. Zahn-Zabal M, Kobr M, Girod P a, Imhof M, Chatellard P, de Jesus M, Wurm F, Mermod N.
Development of stable cell lines for production or regulated expression using matrix attachment
regions. J. Biotechnol. 2001; 87:29–42. [PubMed: 11267697]
77. Antoniou M, Harland L, Mustoe T, Williams S, Holdstock J, Yague E, Mulcahy T, Griffiths M,
Edwards S, Ioannou P, Mountain A, Crombie R. Transgenes encompassing dual-promoter CpG
islands from the human TBP and HNRPA2B1 loci are resistant to heterochromatin-mediated
silencing. Genomics. 2003; 82:269–279. [PubMed: 12906852]
78. Williams S, Mustoe T, Mulcahy T, Griffiths M, Simpson D, Antoniou M, Irvine A, Mountain A,
Crombie R. CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing
and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells. BMC
Biotechnol. 2005; 5:17. [PubMed: 15935093]
79. Zhang F, Thornhill SI, Howe SJ, Ulaganathan M, Schambach A, Sinclair J, Kinnon C, Gaspar HB,
Antoniou M, Thrasher AJ. Lentiviral vectors containing an enhancer-less ubiquitously acting
chromatin opening element (UCOE) provide highly reproducible and stable transgene expression
in hematopoietic cells. Blood. 2007; 110:1448–1457. [PubMed: 17456723]
NIH-PA Author Manuscript

80. Zhang F, Frost AR, Blundell MP, Bales O, Antoniou MN, Thrasher AJ. A ubiquitous chromatin
opening element (UCOE) confers resistance to DNA methylation-mediated silencing of lentiviral
vectors. Mol. Ther. 2010; 18:1640–1649. [PubMed: 20588258]
81. Ye J, Alvin K, Latif H, Hsu A, Parikh V, Whitmer T, Tellers M, de la Cruz Edmonds MC, Ly J,
Salmon P, Markusen JF. Rapid protein production using CHO stable transfection pools.
Biotechnol. Prog. 2010; 26:1431–1437. [PubMed: 20564356]
82. Sautter K, Enenkel B. Selection of high-producing CHO cells using NPT selection marker with
reduced enzyme activity. Biotechnol. Bioeng. 2005; 89:530–538. [PubMed: 15669091]
83. Ho SCL, Bardor M, Feng H, Mariati, Tong YW, Song Z, Yap MGS, Yang Y. IRES-mediated
Tricistronic vectors for enhancing generation of high monoclonal antibody expressing CHO cell
lines. J. Biotechnol. 2012; 157:130–139. [PubMed: 22024589]
84. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high-expression transfectants with a
novel eukaryotic vector. Gene. 1991; 108:193–199. [PubMed: 1660837]
85. Westwood AD, Rowe DA. Clarke HRG Improved recombinant protein yield using a codon
deoptimized DHFR selectable marker in a CHEF1 expression plasmid. Biotechnol. Prog. 26:1558–
1566. [PubMed: 20949444]
86. Zhang R, Shen W. Monoclonal antibody expression in Mammalian cells. Antib. Eng. 2012;
907:341–358.
NIH-PA Author Manuscript

87. Urlaub G, Käs E, Carothers AM, Chasin LA. Deletion of the diploid dihydrofolate reductase locus
from cultured mammalian cells. Cell. 1983; 33:405–412. [PubMed: 6305508]
88. Kaufman RJ, Sharp PA. Amplification and expression of sequences cotransfected with a modular
dihydrofolate reductase complementary dna gene. J. Mol. Biol. 1982; 159:601–621. [PubMed:
6292436]
89. Ng SK, Wang DIC, Yap MGS. Application of destabilizing sequences on selection marker for
improved recombinant protein productivity in CHO-DG44. Metab. Eng. 2007; 9:304–316.
[PubMed: 17368064]
90. Ng SK, Tan TRM, Wang Y, Ng D, Goh L-T, Bardor M, Wong VVT, Lam KP. Production of
Functional Soluble Dectin-1 Glycoprotein Using an IRES-Linked Destabilized-Dihydrofolate
Reductase Expression Vector. PLoS One. 2012; 7:e52785. [PubMed: 23300776]
91. Barnes LM, Bentley CM, Dickson a J. Advances in animal cell recombinant protein production:
GS-NS0 expression system. Cytotechnology. 2000; 32:109–123. [PubMed: 19002973]

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 14

92. Pu H, Cashion LM, Kretschmer PJ, Liu Z. Rapid establishment of high-producing cell lines using
dicistronic vectors with glutamine synthetase as the selection marker. Mol. Biotechnol. 1998;
10:17–25. [PubMed: 9779420]
NIH-PA Author Manuscript

93. Kingston RE, Kaufman RJ, Bebbington CR, Rolfe MR. Amplification using CHO cell expression
vectors. Chapter 16. Curr. Protoc. Mol. Biol. 2002 Unit 16.23.
94. Fan L, Kadura I, Krebs LE, Hatfield CC, Shaw MM, Frye CC. Improving the efficiency of CHO
cell line generation using glutamine synthetase gene knockout cells. Biotechnol. Bioeng. 2012;
109:1007–1015. [PubMed: 22068567]
95. Orfao, a; Ruiz-Arguelles, a. General concepts about cell sorting techniques. Clin. Biochem. 1996;
29:5–9. [PubMed: 8929817]
96. Young SM, Bologa C, Prossnitz ER, Oprea TI, Sklar L a, Edwards BS. High-throughput screening
with HyperCyt flow cytometry to detect small molecule formylpeptide receptor ligands. J. Biomol.
Screen. 2005; 10:374–382. [PubMed: 15964939]
97. Ibrahim SF, van den Engh G. High-speed cell sorting: fundamentals and recent advances. Curr.
Opin. Biotechnol. 2003; 14:5–12. [PubMed: 12565996]
98. Song M, Raphaelli K, Jones ML, Aliabadi-Zadeh K, Leung KM, Crowley D, Hughes B, Mahler S,
Gray PP, Huang EP, Chin DY. Clonal selection of high producing, stably transfected HEK293 cell
lines utilizing modified, high-throughput FACS screening. J. Chem. Technol. Biotechnol. 2011;
86:935–941.
99. Pichler J, Hesse F, Wieser M, Kunert R, Galosy SS, Mott JE, Borth N. A study on the temperature
dependency and time course of the cold capture antibody secretion assay. J. Biotechnol. 2009;
NIH-PA Author Manuscript

141:80–83. [PubMed: 19428734]

100. Yoshikawa T, Nakanishi F, Ogura Y, Oi D, Omasa T, Katakura Y, Kishimoto M, Suga KI. Flow
cytometry: an improved method for the selection of highly productive gene-amplified CHO cells
using flow cytometry. Biotechnol. Bioeng. 2001; 74:435–442. [PubMed: 11427945]
101. Durocher Y, Butler M. Expression systems for therapeutic glycoprotein production. Curr. Opin.
Biotechnol. 2009; 20:700–707. [PubMed: 19889531]
NIH-PA Author Manuscript

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 15
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 1.
US sales of top nine classes of biologic drugs in 2011. Adapted from Aggarwal et. al. [6]
NIH-PA Author Manuscript

FEBS Lett. Author manuscript; available in PMC 2015 January 21.

 Bandaranayake and Almo Page 16
NIH-PA Author Manuscript
NIH-PA Author Manuscript

Figure 2.
Timelines for gene delivery and production methods. Standard protocol for generating stable
producer lines and scaling up to reactor size shown on top. This process is compared to
transient gene expression (TGE), Recombinase mediated cassette exchange (RMCE) and
Lentivirus driven integration (LVs).
NIH-PA Author Manuscript

FEBS Lett. Author manuscript; available in PMC 2015 January 21.